Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

Eli Lilly said on Wednesday it is partnering with Walmart to sell its weight-loss treatment Zepbound at the retailer's ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

Pharma giant Eli Lilly tapped Walmart to offer in-store pickups of Zepbound vials, marking the first retail collaboration for ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...